Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Genetic Screens

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...

In Vitro Drug Release Testing: Overview, Development and Validation

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A conceptual matrix model of patient involvement and patient expertise in medicines and medical technology research and development.

Research involvement and engagement·2026

Same author

Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Comparison of the enzymatic and cellular profiles of clinical JAK inhibitors for the treatment of myelofibrosis.

Blood neoplasia·2026

Same author

Spotlight on Sjögren's: a patient perspective on burden of illness and unmet needs - results from a real-world survey.

RMD open·2026

Same author

Digital adaptation of the clinically effective REACH-HF home-based cardiac rehabilitation programme for people living with heart failure (D:REACH-HF).

Digital health·2025

Same journal

Functional Comparison of Neuronal Cells Differentiated from Human Induced Pluripotent Stem Cell-Derived Neural Stem Cells under Different Oxygen and Medium Conditions.

Journal of biomolecular screening·2017

Same journal

Development of an In Vitro Model to Screen CYP1B1-Targeted Anticancer Prodrugs.

Journal of biomolecular screening·2017

Same journal

Erratum.

Journal of biomolecular screening·2017

Same journal

Software, Database, and Information Services.

Journal of biomolecular screening·2017

Same journal

High-Throughput Platform for Identifying Molecular Factors Involved in Phenotypic Stabilization of Primary Human Hepatocytes In Vitro.

Journal of biomolecular screening·2016

Same journal

SLAS Europe High-Content Screening Conference in Dresden: A Glimpse of the Future?

Journal of biomolecular screening·2016

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

Published on: March 3, 2015

Process validation and screen reproducibility in high-throughput screening.

Isabel Coma¹, Liz Clark, Emilio Diez

¹GlaxoSmithKline R&D Pharmaceuticals, Screening and Compound Profiling, Tres Cantos, Spain. isabel.coma@gsk.com

Journal of Biomolecular Screening

|January 28, 2009

Summary

This summary is machine-generated.

This study details GlaxoSmithKline

More Related Videos

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening

Published on: January 17, 2014

High Content Screening in Neurodegenerative Diseases

High Content Screening in Neurodegenerative Diseases

Published on: January 6, 2012

Related Experiment Videos

Last Updated: Jun 26, 2026

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

Published on: March 3, 2015

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening

Published on: January 17, 2014

High Content Screening in Neurodegenerative Diseases

High Content Screening in Neurodegenerative Diseases

Published on: January 6, 2012

Area of Science:

Drug discovery
Chemical genomics
High-throughput screening

Background:

Large-scale compound screening is crucial in pharmaceutical, biotech, and academic research.
High-throughput screening (HTS) requires substantial resources and necessitates quality control.
Ensuring reproducibility and result quality is vital before costly HTS campaigns.

Purpose of the Study:

To present GlaxoSmithKline's (GSK) approach to validating high-throughput screening processes.
To detail methods for optimizing HTS workflows and ensuring quality.
To describe statistical evaluations for HTS reproducibility and compound activity discrimination.

Main Methods:

Optimization and validation of the HTS workflow as a quality process.
Statistical evaluation of HTS, focusing on reproducibility.
Adaptation and implementation of reproducibility indexes from medical diagnostics.

Main Results:

GSK has developed a validation process for HTS campaigns.
The process includes workflow optimization and statistical analysis of reproducibility.
Case studies demonstrate the practical application of these validation tools.

Conclusions:

A robust validation process is essential for successful and cost-effective HTS.
Statistical methods and reproducibility indexes enhance the reliability of HTS results.
GSK's approach provides a framework for quality assurance in drug discovery screening.